CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 27 enrolled
Drug / intervention
F18-FPPRGD2drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01383135
NCT01383135Early Ph 1Completed
CompareCT.gov

Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2

Stanford University·interventional·Posted Jun 28, 2011·Updated Jan 12, 2024

In Brief

A Early Phase 1 clinical trial evaluating F18-FPPRGD2 for Breast Cancer and 3 related conditions. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The purpose of the study was to conduct a pilot test of new tracers (\[18F\]FPRGD2 and \[18F\]FPPRGD2) to define normal tracer biodistribution (where the tracer goes), stability (how much metabolises), pharmacokinetics (how much stays in which organs and for how long), and radiation dosimetry (organ radiation dose). Healthy volunteers provided the normal biodistribution data. The same radiopharmaceutical was also tested in breast cancer, glioblastoma multiform (brain cancer), and lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Non-Small-Cell Lung Cancer, Glioblastoma, Other Cancers
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 28, 2011
Enrollment StartOct 1, 2010
Primary CompletionApr 1, 2012
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.0 years ago

Interventions

F18-FPPRGD2drug

Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).